Zelluna Asa · OSL:ZLNA
Zelluna Asa — Ultimovacs — Q1 2021 Earnings Presentation
21 slides from Zelluna Asa's earnings presentation, May 11, 2021
Slide 1: Enabling the immune system to fight cancer – First quarter 2021 presentation
Enabling the immune system to fight cancer First quarter 2021 presentation 11 May 2021 Carlos de Sousa, CEO Jens Bjørheim, CMO Hans Vassgård Eid, CFO Non-Confidential, Ultimovacs copy and distribution rights 1
Slide 2: Important notice and Disclaimer
Important notice and Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Ultimovacs’ business, financia
Slide 3: Table of contents
Table of contents Highlights Q1 2021 Operational update Q1 2021 Key financials Q1 2021 & Newsflow Non-Confidential, Ultimovacs copy and distribution rights 3
Slide 4: Highlights Q1 2021
Highlights Q1 2021 UV1 Phase II program extended to four trials – more than 500 patients to be enrolled • INITIUM (154 patients): Ultimovacs sponsored trial in malignant melanoma in which UV1 is combined with nivolumab and ipilimumab. • NIPU (118 patients): trial in mesothelioma, UV1 in combination
Slide 5: Highlights Q1 2021 (cont.)
Highlights Q1 2021 (cont.) Ongoing patient recruitment in the INITIUM, NIPU and TENDU trials • INITIUM: 40 out of 154 patients enrolled (24 enrolled as of Q4 2020 reporting) • NIPU: 29 out of 118 patients enrolled (18 enrolled as of Q4 2020 reporting) • TENDU: the first cohort of three patients has
Slide 6: Highlights Q1 2021 (cont.)
Highlights Q1 2021 (cont.) Poster presentation at ASCO • An abstract on the Company’s Phase I trial evaluating its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab in patients with metastatic malignant melanoma has been accepted for a poster presentation at t
Slide 7: Table of contents
Table of contents Highlights Q1 2021 Operational update Q1 2021 Key financials Q1 2021 & Newsflow Non-Confidential, Ultimovacs copy and distribution rights 7
Slide 8: Broad Development Pipeline: more than 500 patients in Phase II
Broad Development Pipeline: more than 500 patients in Phase II Indication Clinical trial information Preclinical Phase I Phase II Phase III Partner/Collaboration Prostate cancer Conducted at OUS, 22 patients. Completed in 2015 Oslo University Hospital Non-small cell lung Conducted at OUS, 18 patient
Slide 9: INITIUM and NIPU are ongoing Phase II trials
INITIUM and NIPU are ongoing Phase II trials INITIUM NIPU • Randomized Phase II trial in 1st line treatment of patients with • Randomized Phase II trial in 2nd line malignant pleural mesothelioma metastatic malignant melanoma • Sponsored by Oslo University Hospital in collaboration with BMS • Ultimo
Slide 10: DOVACC and FOCUS are Phase II trials soon to be started
DOVACC and FOCUS are Phase II trials soon to be started DOVACC FOCUS • Randomized Phase II second maintenance trial in BRCA negative • Randomized phase II trial in patients with recurrent or ovarian cancer patients metastatic PDL1 positive head and neck cancer • Sponsored by NSGO/ENGOT in collaborat
Slide 11: The TET-platform and the TENDU trial
The TET-platform and the TENDU trial The TET-platform (Tetanus-Epitope Targeting) • Next-generation vaccine technology expanding Ultimovacs’ product pipeline • Promising approach to strengthen and increase T cell responses against cancer-specific peptides by combining antigens and the vaccine adjuva
Slide 12: The TET-platform and the TENDU trial (cont.)
The TET-platform and the TENDU trial (cont,) • This trial will investigate a prostate cancer specific vaccine based on the TET technology • The main objective is to assess the safety of the TET technology • The TENDU trial will be conducted at Oslo University Hospital, and 9-12 patients will be enro
Slide 13: Table of contents
Table of contents Highlights Q1 2021 Operational update Q1 2021 Key financials Q1 2021 & Newsflow Non-Confidential, Ultimovacs copy and distribution rights 13
Slide 14: Key financials
Key financials Comments: Key financials per Q1-2021 - Ultimovacs Group NOK (000) Q1-20 0 Q1-21 FY20 Payroll expenses Total revenues - - 0 - ▪ Higher cost in Q1-21 than same period in 2020 due to: Payroll and payroll related expenses 10 015 12 203 50 989 ▪ higher share-option costs this quarter Exter
Slide 15: Key financials – operating cash flow
Key financials – operating cash flow NOK (000) – Negative amounts Comments: • The negative operating cashflow in Q1-21 is at the same level as in previous quarters in 2020 • A further increase in operating cashflow related to R&D should be expected in 2021 with the initiation of the two new phase II
Slide 16: Key financials – quarterly overview
Key financials – quarterly overview Key financials per Q1-2021 - Ultimovacs Group NOK (000) Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Total revenues - - - - - Payroll and payroll related expenses 10 015 13 197 13 115 14 662 12 203 External R&D and IPR expenses (incl. grants) 18 089 19 938 15 307 7 537 16 012 Ot
Slide 17: Recent and expected newsflow 2020-2021
Recent and expected newsflow 2020-2021 2020 2021 Q4 Q1 Q2 Q3 Q4 First patient in the Signed agreements on the DOVACC Phase II DOVACC Phase II trial trial Signed agreements on the First patient in the FOCUS Phase II trial FOCUS Phase II trial Poster 5-years overall 1 and 2-year observation presentati
Slide 18: Event calendar
Event calendar 19 May 2021 at 23.00 CEST: ASCO Release of abstract 20 May 2021 at 10.00 CEST: Ultimovacs webcast presenting the data 20 May 2021 at 19:25 CEST: Presentation at the Sachs Immuno-Oncology Forum 20 May 2021 at 14:00 CEST: Participation in the RADIUM podcast 25 May 2021 at 16:00 CEST: Pr
Slide 19: Key take-aways from Q1 report
Key take-aways from Q1 report • UV1 Phase II program extended to four trials – more than 500 patients to be enrolled • Patient recruitment in the INITIUM and NIPU trials is proceeding despite COVID-19 challenge • Poster presentation at the 2021 ASCO Annual meeting: ASCO has accepted an abstract from
Slide 20: Q&A
Q&A
Slide 21: For questions
Enabling the immune system to fight cancer For questions Carlos de Sousa, CEO Hans Vassgård Eid, CFO carlos.desousa@ultimovacs.com hans.eid@ultimovacs.com +47 908 92507 +47 482 48632 www.ultimovacs.com